Dermatology Reports最新文献

We report the case of a 50-year-old woman with severe palmoplantar psoriasis who developed alopecia areata (AA) 2 months after initiating treatment with tildrakizumab (100 mg subcutaneously). The patient had no personal or familial history of autoimmune disorders, and the diagnosis of AA was confirmed by clinical and trichoscopic evaluation. Tildrakizumab was discontinued, and the patient was treated with topical corticosteroids and low-dose oral methylprednisolone, achieving complete hair regrowth within 6 months. Psoriasis subsequently recurred, and treatment was successfully switched to bimekizumab, with sustained remission and no adverse events. To the best of our knowledge, published reports of new-onset alopecia areata during tildrakizumab therapy for psoriasis are lacking. The temporal correlation, lack of confounding risk factors, and resolution upon drug withdrawal suggest a causal relationship. This case expands the spectrum of paradoxical reactions (PRs) to biologic therapies and highlights the need for vigilance regarding autoimmune manifestations during interleukin (IL)-23 inhibition.

Dear Editor, PHACE(S) syndrome is a neurocutaneous disorder associated with segmental infantile hemangiomas (IHs). These hemangiomas typically manifest as rapidly growing lesions on the face or upper trunk. However, this case presents an unusual phenotype - an IH with minimal or arrested growth (IHMAG). [...].

Dear Editor, Lichen planus pigmentosus (LPP) is a chronic inflammatory dermatosis mainly reported in adults from the Indian subcontinent and the Middle East. Pediatric cases are exceedingly rare, and LPP involving the scalp has not been previously described. Given the paucity of literature on childhood LPP, we present a case that broadens the spectrum of clinical presentations of this disease. [...].

Dear Editor, Granuloma annulare is a chronic inflammatory skin disorder characterized by annular dermal papules and plaques. While localized forms often resolve spontaneously, generalized granuloma annulare tends to persist and frequently proves resistant to conventional therapies. The pathogenesis of the disease remains unclear, but increasing evidence suggests a dysregulated immune response involving T cells, macrophages, and cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and interferon-gamma (IFN-γ). [...].

Dear Editor, Pityriasis versicolor (PV) is a superficial mycosis caused by Malassezia species and most often affects the trunk and upper limbs. Flexural or inverse variants, however, may differ markedly from classical morphology due to the influence of moisture, temperature, and friction. These atypical presentations frequently mimic erythrasma, candidal intertrigo, tinea cruris, seborrheic dermatitis, and pigmentary disorders. [...].

Dear Editor, In recent years, many individuals have turned to the Internet for health-related information, a phenomenon commonly referred to as "Dr. Google". While accessible, this practice often exposes users to unverified content, potentially leading to confusion and anxiety. With the rise of artificial intelligence (AI), the landscape is shifting: tools like ChatGPT offer structured, conversational responses. But how reliable are these answers, especially in the medical field? [...].

Eosinophilic annular erythema (EAE) is a rare, benign dermatosis characterized by recurrent erythematous-urticarial plaques and tissue eosinophilia. Its cause is unknown, though it may involve hypersensitivity to an unidentified antigen. EAE typically follows a chronic, relapsing course, affecting the trunk and extremities. Treatment guidelines are lacking, and therapy responses vary. This study presents four new cases and reviews current treatment options. Four patients with EAE, aged 20 to 72, were treated at Galliera Hospital (Genova, Italy). They exhibited erythematous, annular lesions on the trunk or extremities with variable pruritus. Histology confirmed eosinophilic inflammation without flame figures. Previous systemic steroid treatments provided partial improvement but resulted in relapse. Topical clobetasol improved symptoms in two of three patients, while systemic methylprednisolone also showed benefit. However, one patient on topical clobetasol and another on systemic methylprednisolone were lost to follow-up. A search in PubMed until July 2024 identified English-language articles with histologically confirmed EAE and clear treatment outcomes. Antimalarial drugs, dapsone, and corticosteroids were the most frequently prescribed nonbiological therapies leading to disease control. Other effective treatments in individual cases included nicotinamide, doxycycline, and narrow-band ultraviolet-B (UV-B) phototherapy. Biological drugs such as dupilumab, benralizumab, and mepolizumab showed promising results. The treatment of EAE remains challenging, with many cases resistant to antimalarials, dapsone, and corticosteroids. Further research is necessary to identify more effective treatments. Targeting T-helper 2 (Th2)-type cytokines with specific antibodies may offer a promising approach for refractory EAE, potentially providing a rapid and sustained clinical response.

Dear Editor, In April 2024, a 24-year-old non-smoker female patient with controlled asthma presented with a sore throat, left-sided cervical lymphadenopathy, and a painful, red maculopapular rash on the hands and feet. [...].

A 75-year-old male presented to the dermatology department with a primary complaint of a tumorous lesion, measured 4 cm × 3 cm in diameter, located in the right preauricular region. Histological evaluation revealed a basal cell carcinoma, and surgical excision under local anesthesia was recommended.

A 54-year-old male presented with a painful nodular, tumor-like lesion, in the right occipital region, present for approximately two years, clinically suspected of atheroma. Surgical excision of the lesion was recommended.